Search results
Results from the WOW.Com Content Network
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers.The editor-in-chief is Ruiwen Zhang (UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry.
The American Society of Health-System Pharmacists (ASHP) reported that 323 "active medication shortages" were reported in January–March 2024. As a result of drug scarcity, many healthcare systems were forced to either ration out essential drugs, triage patients based on the severity of their condition and their need for the drug, or both.
The targets and drugs in TTD cover 583 protein biochemical classes and 958 drug therapeutic classes, respectively. [1] The latest version of the International Classification of Diseases (ICD-11) codes released by WHO are incorporated in TTD to facilitate the clear definition of disease/disease class.
Journal of Drug Targeting is a peer-reviewed medical journal published by Informa that covers research on all aspects of drug delivery and drug targeting for molecular and macromolecular drugs. The editor in chief is Saghir Akhtar (College of Medicine, Qatar University ).
move to sidebar hide. From Wikipedia, the free encyclopedia
Drug Discovery Today is a monthly peer-reviewed scientific journal that is published by Elsevier.It was established in 1996 and publishes reviews on all aspects of preclinical drug discovery from target identification and validation through hit identification, lead identification and optimisation, to candidate selection.
The drug or other substance has a high potential for abuse. The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse of the drug or other substances may lead to severe psychological or physical dependence.
Drug Target Insights is a peer-reviewed open access academic journal focusing on drug treatment targets and clinical therapeutics. The journal was founded in 2006 by Monica Milani and is currently edited by Giulio Zuanetti .